Sickle Cell Gene Therapy and Cure: Casgevy, Lyfgenia and Cost
A quick guide for patients, caregivers, and advocates: what today's standard sickle cell treatments do, how the new gene therapies work, and why they come with multi-million-dollar price tags.
What is sickle cell disease?
Sickle cell disease (SCD) is an inherited blood disorder caused by a mutation in haemoglobin, the protein that carries oxygen in red blood cells (NHLBI). It makes cells stiff and crescent-shaped, causing painful blockages, organ damage, and anaemia. Treatment has historically lagged partly because SCD disproportionately affects Black, Middle Eastern, Mediterranean, and South Asian communities, and research funding hasn't matched the disease burden — and partly because true cures require fixing the bone marrow itself, a far harder task than developing a pill.
Current standard treatments
- Hydroxyurea — oral medication that boosts protective fetal haemoglobin, reducing pain crises.
- Pain management — acute and preventive strategies, individualised to each patient.
- Blood transfusions — prevent strokes and complications, though they carry risks like iron overload.
- Other medicines, depending on where you live — availability differs by country. L-glutamine (Endari) is approved in the US but was not authorised in the EU (EMA). Crizanlizumab (Adakveo) is still approved in the US, but its licence was revoked in the EU in 2023 and in the UK in 2024 after a larger study did not confirm its benefit (EMA, NICE). Your haematologist can tell you what is available to you.
- Bone marrow transplant — the long-standing cure, but it requires a closely matched donor (often a sibling) and carries risks like graft-versus-host disease.
Voxelotor (Oxbryta), once among these newer medicines, was withdrawn worldwide by its maker in September 2024 because new data suggested its benefits no longer outweighed its risks (Pfizer). If you used to take it, your care team can talk you through alternatives.
The new gene therapies
In December 2023, the FDA approved two landmark gene therapies (FDA):
Casgevy (exagamglogene autotemcel) — the first CRISPR-based therapy approved in the U.S. It edits a patient's own stem cells to turn off a gene (BCL11A) that suppresses fetal haemoglobin, letting the body make its own non-sickling haemoglobin again. Originally approved for ages 12+, its US approval was expanded in July 2026 to children as young as 2 (Healio).
Lyfgenia (lovotibeglogene autotemcel) — uses a disabled virus to add a new gene, prompting cells to produce a modified, non-sickling haemoglobin. It carries an FDA boxed warning for a rare blood cancer risk seen in trials.
Both use the patient's own cells (no donor needed), but the process is intensive: cells are collected, chemotherapy clears the bone marrow, modified cells are infused, and recovery takes months.
Can I get gene therapy on the NHS?
In England, NICE approved Casgevy for NHS use in early 2025 under a managed access arrangement, for some people aged 12 and over with severe sickle cell disease and recurrent crises (NICE). It is generally aimed at people who would be suitable for a stem cell transplant but don't have a matched donor, and it is delivered at a small number of specialist centres. Lyfgenia is not approved for use in the UK. Your haematology team is the right starting point if you want to know whether a referral makes sense for you.
Who is eligible for sickle cell gene therapy?
Eligibility depends on where you live and on your own medical picture, but the approvals so far share a common thread: these treatments are for people whose sickle cell is causing recurrent severe pain crises, and who are well enough to go through high-dose chemotherapy. Your team will also look at your sickle cell type, your organ health, and whether a matched-donor transplant is an option instead.
Because "recurrent severe crises" is at the heart of eligibility, a clear record of how often you've had crises, how bad they were and whether you needed hospital care is genuinely useful when you have that conversation.
What's on the horizon?
Investigational approaches — not yet proven or approved — include newer, more precise gene-editing tools (like base editing), expanded half-matched transplant techniques, and early research into editing cells directly inside the body. All remain years from potential widespread use.
What does this mean for patients?
These therapies aren't for everyone — they're approved for specific patients with recurrent severe pain crises, and the process is physically demanding, with real risks including infertility from chemotherapy conditioning. For those who qualify, trial data show many patients free of severe crises for extended periods, but long-term durability data is still developing. Every option — standard care, transplant, or gene therapy — should be a personalised decision made with your haematology team.
Why are gene therapies so expensive?
Casgevy costs about $2.2 million and Lyfgenia about $3.1 million per patient. Reasons include:
- Massive R&D costs spread across a relatively small patient population.
- Personalised manufacturing — each treatment is made for one patient, not mass-produced.
- Specialised treatment centres and trained staff are needed to deliver it.
- Complex insurance negotiations, especially with Medicaid, which covers many SCD patients.
The bottom line
This is a genuine turning point for sickle cell disease — the first approved cures outside of donor-dependent transplant. But real hope has to sit alongside real honesty: these treatments are demanding, not universally accessible, and extremely expensive, raising serious equity questions about who actually gets to benefit. Talk with your care team about what these advances mean for you, and consider supporting advocacy efforts pushing for broader access.
Frequently asked questions
This guide is general information, not medical advice. Always follow the plan agreed with your own care team. Read our medical disclaimer.
Related guides
The different types of sickle cell disease explained — HbSS, HbSC, HbS beta-zero and beta-plus thalassaemia, HbSD and HbSE — and how they differ.
Everything in one place: what sickle cell disease (sickle cell anaemia) is, symptoms, crises, types, treatment, daily life, rights and getting good care.